Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy.
about
Cardiac toxicity of trastuzumab in elderly patients with breast cancerMultimodality Imaging in CardiooncologyEvaluation and management of patients with heart disease and cancer: cardio-oncologyStrain imaging to detect cancer therapeutics-related cardiac dysfunction: are we there yet?Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs.Cardiac imaging approaches to evaluate drug-induced myocardial dysfunctionNoninvasive diagnosis of chemotherapy related cardiotoxicityDiagnostic and prognostic value of cardiovascular magnetic resonance in non-ischaemic cardiomyopathies.Review of Journal of Cardiovascular Magnetic Resonance 2009Diagnostic Strategies for Early Recognition of Cancer Therapeutics-Related Cardiac Dysfunction.The art of healing broken hearts in breast cancer patients: Trastuzumab and heart failure.Nuclear imaging in detection and monitoring of cardiotoxicity.Longitudinal assessment of concurrent changes in left ventricular ejection fraction and left ventricular myocardial tissue characteristics after administration of cardiotoxic chemotherapies using T1-weighted and T2-weighted cardiovascular magnetic rAn update on cardio-oncology.Managing chemotherapy-related cardiotoxicity in survivors of childhood cancers.Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer.Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 1: Definitions, Pathophysiology, Risk Factors, and Imaging.Risk factors for anthracycline-associated cardiotoxicity.Identifying the etiology: a systematic approach using delayed-enhancement cardiovascular magnetic resonance.Benefits of antihypertensive medications for anthracycline- and trastuzumab-induced cardiotoxicity in patients with breast cancer: Insights from recent clinical trials.Biological drugs: classic adverse effects and new clinical evidences.Severe heart failure after bortezomib treatment in a patient with multiple myeloma: a case report and review of the literature.Cardiac toxicity of anticancer agents.Traditional and novel methods to assess and prevent chemotherapy-related cardiac dysfunction noninvasively.Catching broken hearts: pre-clinical detection of doxorubicin and trastuzumab mediated cardiac dysfunction in the breast cancer setting.Cardiotoxicity due to chemotherapy: role of cardiac imaging.Heart failure and chemotherapeutic agents.Current and emerging modalities for detection of cardiotoxicity in cardio-oncology.Detection of late radiation damage on left atrial fibrosis using cardiac late gadolinium enhancement magnetic resonance imaging.Comprehensive review on cardio-oncology: Role of multimodality imaging.Cardiac MRI: a Translational Imaging Tool for Characterizing Anthracycline-Induced Myocardial Remodeling.Role of Imaging in Cardio-Oncology.Echocardiography signs of early cardiac impairment in patients with breast cancer and trastuzumab therapy.Baseline diastolic dysfunction as a predictive factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancer.Utility of prechemotherapy echocardiographical assessment of cardiac abnormalities.The role and clinical effectiveness of multimodality imaging in the management of cardiac complications of cancer and cancer therapy.Diagnosis, Treatment, and Prevention of Cardiovascular Toxicity Related to Anti-Cancer Treatment in Clinical Practice: An Opinion Paper from the Working Group on Cardio-Oncology of the Korean Society of Echocardiography.
P2860
Q26741182-D7226D14-4A96-46AF-8C12-95E524D230C8Q26795452-4DCDEA8D-0B1C-4E0B-A7F0-D9B5C97343DDQ26998273-FA1A6523-827E-4628-9015-EE3DF4850ECCQ30385954-4FC33997-0440-4196-970B-9262C6DB002DQ30427656-B7DD08D4-01DD-40E1-B40F-456BC3E9103BQ30446453-4E938261-4E7E-4A7D-A36B-C38CDAA6A3AEQ30461444-AAFCE4CE-8381-492A-AA9B-1CD88C889412Q30463822-3E488195-1635-41CA-AAA0-7A3E18C05F03Q30484444-29060CC7-A10D-4BCB-8589-0EE8028C2B5AQ33565936-DBCA5A37-6965-484F-B67D-301B755B4093Q33595716-8401B7F3-EF9A-47C1-9688-0427B494AEE2Q33942611-536EC676-A0C8-48BE-8DA5-ACD933A17D95Q34560383-B9650750-EC33-4FF4-8AA5-B0C3A4733C94Q34650059-AA107431-8D45-4D63-847F-D6258E63E78FQ35562745-EDB2F38E-DF2B-4422-A714-14B5D910D96BQ35880224-4728DCC5-E90D-4F7A-9517-7369EC512DA2Q36451899-A9080431-12BF-4973-AD98-07B020F63DCDQ36921775-F2A235F6-0956-48ED-94DF-682FAD0F341BQ37248274-4756D417-82CF-4E2B-99B3-DD68AB04A29EQ37311943-13CE9CD9-7F24-4339-9A9C-38D3701CB062Q38015746-10224EC0-9E60-46F2-ADC1-6901BCF85C7DQ38042295-F4F4F879-AE36-4CEE-8289-102CBEC5CA49Q38091377-D1E4EBB2-C080-46C9-859B-D5B245F51442Q38097736-E56C4175-A066-4CE5-A271-DAD5229BB447Q38222800-BC001FD1-1D1E-4CF6-BAEF-0BEB0AF82D58Q38343043-E2748C1E-AA97-482D-B1DE-BE19E4B4966AQ38559133-A012E82C-0C3A-430C-8CAB-950E8E5A209FQ38559474-8F50EDC2-ED15-4081-A2DE-1EBD1B92FED3Q38663202-755B9D7A-2868-48DC-9B4F-EC22B12F09E6Q38844387-FB643FF1-B40F-48B8-8303-FB38C7D69184Q38862688-4D81DA3A-FB3C-49D5-B1E1-8BE71C04C63EQ39285218-AE63B38C-F2B8-4C21-818B-347CB92A4447Q51367703-A7F4A9B6-05C6-4B30-B07A-FFA436108F18Q51368192-AAF82A13-5E88-4E5D-ADA6-1FA61FD369F6Q51530456-E298CEAB-2E4E-4487-89B2-4BA5E0DAA037Q52982588-C4ED65A4-5CBE-4B9C-A80C-AF66EA588D58Q53075042-69236BA7-5810-42B3-A20C-FAF1464A98DE
P2860
Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Delayed contrast enhancement c ...... uzumab induced cardiomyopathy.
@ast
Delayed contrast enhancement c ...... uzumab induced cardiomyopathy.
@en
type
label
Delayed contrast enhancement c ...... uzumab induced cardiomyopathy.
@ast
Delayed contrast enhancement c ...... uzumab induced cardiomyopathy.
@en
prefLabel
Delayed contrast enhancement c ...... uzumab induced cardiomyopathy.
@ast
Delayed contrast enhancement c ...... uzumab induced cardiomyopathy.
@en
P2093
P2860
P356
P1476
Delayed contrast enhancement c ...... uzumab induced cardiomyopathy.
@en
P2093
Davinder S Jassal
Iain Kirkpatrick
Matthew Lytwyn
Nazanin Fallah-Rad
Tielan Fang
P2860
P2888
P356
10.1186/1532-429X-10-5
P577
2008-01-22T00:00:00Z
P5875
P6179
1019366116